These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24706642)

  • 21. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
    Mato AR; Samp JC; Gauthier G; Terasawa E; Brander DM
    Cancer Biol Ther; 2018 Jul; 19(7):636-643. PubMed ID: 29584544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
    Maffei R; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
    J Hematol Oncol; 2015 May; 8():60. PubMed ID: 26022368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.
    Woyach JA
    Hematology Am Soc Hematol Educ Program; 2015; 2015():355-60. PubMed ID: 26637743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 25. B cell receptor inhibition as a target for CLL therapy.
    Jeyakumar D; O'Brien S
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idelalisib: targeting PI3Kδ in B-cell malignancies.
    Gilbert JA
    Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
    [No Abstract]   [Full Text] [Related]  

  • 27. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
    Molica S
    Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
    Fruman DA; Cantley LC
    N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
    [No Abstract]   [Full Text] [Related]  

  • 29. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Gordon MJ; Huang J; Chan RJ; Bhargava P; Danilov AV
    Br J Haematol; 2021 Feb; 192(4):720-728. PubMed ID: 32599655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising results Halt phase III studies of idelalisib.
    Inman S
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E9. PubMed ID: 25764575
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic lymphocytic leukaemia.
    Hallek M; Shanafelt TD; Eichhorst B
    Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How should we sequence and combine novel therapies in CLL?
    Davids MS
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
    Desai AV; El-Bakkar H; Abdul-Hay M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.
    Man S; Henley P
    Br J Haematol; 2019 Jul; 186(2):220-233. PubMed ID: 30945268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Morabito F; Gentile M; Seymour JF; Polliack A
    Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
    Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idelalisib approved for three blood cancers.
    Traynor K
    Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
    [No Abstract]   [Full Text] [Related]  

  • 40. Ibrutinib: searching for a partner drug.
    Kater AP; Brown JR
    Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.